Rare disease
Steady, with 6 percent growth in Q2 2026.
The numbers
What it is
Treatments for rare, serious conditions, a smaller and more stable business than the GLP-1 franchises.
Why it matters to the stock. A steady, higher-margin business gives the company some ballast when obesity pricing is volatile.
News
FDA extends review of denecimig haemophilia A BLA over manufacturing remediation
The FDA is still reviewing Novo's biologics license application for denecimig, a haemophilia A treatment, and has set no new decision date.
Regulation